drugset / Trial / NCT03234153
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
NaSingle-groupOpen-labelTreatment
Summary
The trial assess the safety and antitumor activity of the anti-PD-L1 antibody Durvalumab in combination with the anti-CTLA4 antibody Tremelimumab.
Timeline
- Start
- 2018-07-15
- Primary completion
- 2019-11-08
- Completion
- 2020-05-18
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |